Skip to main content

Table 2 Investigator-assessed response utilizing RECIST (version: 1.1)

From: Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

Best overall response Anlotinib + oxaliplatin + capecitabine (n = 30)
CR, n (%) 1 (3.3)
PR, n (%) 22 (73.3)
SD, n (%) 5 (16.7)
PD, n (%) 1 (3.3)
NE, n (%) 1 (3.3)
ORRa, n (%, 95%CI) 23 (76.7,57.7–90.1)
DCRb, n (%, 95%CI) 28 (93.3, 77.9–99.2)
  1. RECIST, Response Evaluation Criteria in Solid Tumors; ORR, objective response rate; DCR, disease control rate; CI, confidence interval
  2. aORR was defined as the proportion of patients with a best overall tumor response, CR, or PR
  3. bDCR refers to the proportion of patients with response and stable disease